Peter A. Kaufman, MD, reviews data in patients with HER2+ metastatic breast cancer treated with tucatinib-based therapy.
Peter A. Kaufman, MD
Advertisement
Articles by Peter A. Kaufman, MD
Peter A. Kaufman, MD, Associate Professor of Medicine at the Geisel School of Medicine at Dartmouth, discusses the side effect profiles of the microtubule inhibitor eribulin mesylate and the oral chemotherapeutic agent capecitabine.
Advertisement
Latest Updated Articles
Patient Characteristics, Treatment Patterns, and Clinical Outcomes Associated With Tucatinib Therapy in HER2+ Metastatic Breast CancerPublished: December 20th 2022 | Updated:
Dr. Kaufman on Eribulin/ Capecitabine Side EffectsPublished: February 7th 2013 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5